2022
DOI: 10.1016/j.medengphy.2021.103736
|View full text |Cite
|
Sign up to set email alerts
|

Design and evaluation of an air-insulated catheter for intra-arterial selective cooling infusion from numerical simulation and in vitro experiment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

1
3

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 40 publications
0
2
0
Order By: Relevance
“…Konstas demonstrated that the method including the in vitro study and a numerical theoretical model was an attempt to determine the feasibility of selective brain cooling with intracarotid saline infusion. 20 Our group also used this method to conduct a feasibility assessment on the intravascular interventional catheter 36 and heat exchanger 37 in the IA‐SCAI prototype system.…”
Section: Discussionmentioning
confidence: 99%
“…Konstas demonstrated that the method including the in vitro study and a numerical theoretical model was an attempt to determine the feasibility of selective brain cooling with intracarotid saline infusion. 20 Our group also used this method to conduct a feasibility assessment on the intravascular interventional catheter 36 and heat exchanger 37 in the IA‐SCAI prototype system.…”
Section: Discussionmentioning
confidence: 99%
“…6 More importantly, NHPs are suitable for magnetic resonance imaging, endovascular procedures, long-term functional assessments, behavioral testing, and extensive physiological monitoring. 7,8 However, more efforts are still needed to optimize NHP stroke models in translational studies. For example, in the nerinetide pre-clinical evaluation, their NHP study did not use the approach of alteplase-based reperfusion, leading to a lack of detecting the potential effects of alteplase on nerinetide, which might account for the different effects of nerinetide in the stroke patients receiving alteplase or not in their phase III clinical trial.…”
mentioning
confidence: 99%